Skip to main content

Evgen makes second move for AIM listing

Evgen makes second move for AIM listing

Evgen Pharma is making a fresh bid to become a public company.

The Liverpool-based company, which is focused on treatments for cancer, strokes and Multiple Schlerosis, is looking to join the junior market AIM later this month and is looking to raise approximately £5m through a shares placing.

Its core technology Sulforadex is a patent-protected method of stabilising a synthetic version of sulforaphane, which is a naturally occurring, known anti-cancer agent derived from broccoli and other brassica vegetables.

Chief executive Dr Stephen Franklin said: “The anti-cancer and anti-inflammatory properties of sulforaphane are well documented and are supported by a wealth of published peer-reviewed scientific papers. Our exciting Sulforadex technology stabilises the molecule and unlocks its commercial potential, representing a major breakthrough as a potential therapy in cancer, neurology and other disease areas.

“We intend to advance our programmes in breast cancer, stroke and multiple sclerosis through this IPO on the AIM market of the London Stock Exchange.”


See article in full at